Casdin Capital 13F holdings, Q2 2019
Holdings as of June 30, 2019 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 31 US equity positions worth $1.1bn in its Q2 2019 13F filing. The largest position was SPARK THERAPEUTICS INC at 8.5% of the reported book, followed by INVITAE CORP and 2655787D. Against the Q1 2019 filing, it opened 5 new positions, added to 13 and reduced 3 among the top 31 holdings.
What did Casdin Capital own in Q2 2019? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2019 |
|---|---|---|---|---|---|---|---|
| 1 | SPARK THERAPEUTICS INC | 8.5% | $90.6m | 884,800 | -6% | reduced | |
| 2 | INVITAE CORP | 8.4% | $90.2m | 3,838,388 | 74% | added | |
| 3 | 2655787D BLUEPRINT MEDICINES CORP | 8.3% | $88.7m | 940,000 | 11% | added | |
| 4 | CDXS CODEXIS INC | Healthcare | 8.1% | $86.5m | 5,073,780 | 151% | added |
| 5 | SG7 SAGE THERAPEUTICS INC | 6.9% | $73.2m | 400,000 | 0% | held | |
| 6 | MYOKARDIA INC | 6.0% | $64.4m | 1,285,000 | 0% | held | |
| 7 | FATE FATE THERAPEUTICS INC | Healthcare | 4.8% | $51.8m | 2,550,000 | 0% | held |
| 8 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 4.8% | $50.9m | 335,000 | 10% | added |
| 9 | BLUEBIRD BIO INC | 4.4% | $47.4m | 372,500 | 4% | added | |
| 10 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.4% | $47.2m | 650,000 | 46% | added |
| 11 | MAGENTA THERAPEUTICS INC | 4.1% | $44.3m | 3,003,121 | 14% | added | |
| 12 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 3.7% | $39.4m | 2,428,571 | 0% | held |
| 13 | AUDENTES THERAPEUTICS INC | 3.4% | $36.5m | 965,000 | -4% | reduced | |
| 14 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 2.9% | $30.7m | 1,128,075 | 0% | held |
| 15 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 2.3% | $24.7m | 495,000 | 48% | added |
| 16 | ILMN ILLUMINA INC | Healthcare | 2.1% | $22.1m | 60,000 | 0% | held |
| 17 | GNMK GENMARK DIAGNOSTICS INC | 2.0% | $21.8m | 3,365,000 | 0% | held | |
| 18 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 1.9% | $20.1m | 463,125 | – | new |
| 19 | 2JQ GRITSTONE ONCOLOGY INC | 1.8% | $19.7m | 1,770,000 | 58% | added | |
| 20 | CNST CONSTELLATION PHARMCETICLS I | 1.8% | $18.7m | 1,523,960 | -2% | reduced | |
| 21 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 1.5% | $16.5m | 1,530,000 | 42% | added |
| 22 | GLOBAL BLOOD THERAPEUTICS IN | 1.5% | $15.8m | 300,000 | 0% | held | |
| 23 | HOMOLOGY MEDICINES INC | 1.4% | $14.6m | 745,000 | 113% | added | |
| 24 | EDIT EDITAS MEDICINE INC | Healthcare | 1.1% | $11.9m | 480,000 | 0% | held |
| 25 | ALEC ALECTOR INC | Healthcare | 1.0% | $10.2m | 551,039 | 66% | added |
| 26 | TWST TWIST BIOSCIENCE CORP | Healthcare | 0.8% | $8.7m | 300,000 | – | new |
| 27 | DNLI DENALI THERAPEUTICS INC | Healthcare | 0.8% | $8.3m | 400,000 | 300% | added |
| 28 | CDNA CAREDX INC | Healthcare | 0.7% | $7.2m | 200,000 | 0% | held |
| 29 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.2% | $2.5m | 85,000 | – | new |
| 30 | TURNING POINT THERAPEUTICS I | 0.2% | $2.4m | 60,000 | – | new | |
| 31 | ORCHARD THERAPEUTICS PLC | 0.1% | $1.4m | 100,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.